Most Recent
US lab products giant Beckman Coulter has successfully opposed an Australian biotech's bid to trade mark ‘Cytophex’ for its stem cell expansion system, with an IP Australia delegate finding the mark is too similar to Beckman's ‘CytoFLEX’ mark.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis' appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
An appeals court has found Zip Co infringed the ‘Zip’ trade mark of mortgage provider Firstmac, making orders restraining the buy now, pay later giant from using the name.
Macquarie's fight with a NSW credit union -- which saw the bank's 'Macbank' trade mark cancelled because, a delegate found, it had only been used colloquially -- has landed in the Federal Court.
The founders of carbon credit provider GreenCollar are set to face trial in a case by a company seeking to claw back profits from a business opportunity it says was diverted to other entities in breach of fiduciary duties.
Green iron start-up Element Zero has lost its latest bid to set aside search orders in a case by Fortescue alleging former employees misappropriated its process for carbon dioxide-free iron.
IP boutique FB Rice has hired an IP expert from biotechnology firm CSL Seqirus to head it up a new advisory service.
Hollywood movie giant Warner Bros has lost its opposition to an Australian winemaker's proposed 'Beetlejuice' trade mark.
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.
Fonterra, which has taken cheese maker Bega to court to resolve a dispute over the dairy company's plans to exit the Australian market, is resisting a bid for discovery in the case.